000299783 001__ 299783
000299783 005__ 20250314112220.0
000299783 0247_ $$2doi$$a10.3390/cancers17050879
000299783 0247_ $$2pmid$$apmid:40075726
000299783 037__ $$aDKFZ-2025-00538
000299783 041__ $$aEnglish
000299783 082__ $$a610
000299783 1001_ $$00000-0002-3479-3593$$aKampers, Linde F C$$b0
000299783 245__ $$aThe Complexity of Malignant Glioma Treatment.
000299783 260__ $$aBasel$$bMDPI$$c2025
000299783 3367_ $$2DRIVER$$aarticle
000299783 3367_ $$2DataCite$$aOutput Types/Journal article
000299783 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1741876626_2409$$xReview Article
000299783 3367_ $$2BibTeX$$aARTICLE
000299783 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000299783 3367_ $$00$$2EndNote$$aJournal Article
000299783 520__ $$aMalignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches.
000299783 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000299783 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000299783 650_7 $$2Other$$aimmunotherapy
000299783 650_7 $$2Other$$amalignant glioma
000299783 650_7 $$2Other$$atumor microenvironment
000299783 7001_ $$0P:(DE-He78)eab13a5d37ded394a30e8cef0c57b906$$aMetselaar, Dennis$$b1$$udkfz
000299783 7001_ $$00000-0002-7952-6771$$aVinci, Maria$$b2
000299783 7001_ $$00000-0002-6408-2055$$aScirocchi, Fabio$$b3
000299783 7001_ $$00000-0002-3888-0977$$aVeldhuijzen van Zanten, Sophie$$b4
000299783 7001_ $$00000-0002-8099-5903$$aEyrich, Matthias$$b5
000299783 7001_ $$00000-0003-1486-1736$$aBiassoni, Veronica$$b6
000299783 7001_ $$00000-0001-9256-947X$$aHulleman, Esther$$b7
000299783 7001_ $$00000-0002-9961-4752$$aKarremann, Michael$$b8
000299783 7001_ $$aStücker, Wilfried$$b9
000299783 7001_ $$00000-0002-8102-5968$$aVan Gool, Stefaan W$$b10
000299783 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers17050879$$gVol. 17, no. 5, p. 879 -$$n5$$p879$$tCancers$$v17$$x2072-6694$$y2025
000299783 909CO $$ooai:inrepo02.dkfz.de:299783$$pVDB
000299783 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eab13a5d37ded394a30e8cef0c57b906$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000299783 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000299783 9141_ $$y2025
000299783 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-14
000299783 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2024-12-14
000299783 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000299783 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000299783 980__ $$ajournal
000299783 980__ $$aVDB
000299783 980__ $$aI:(DE-He78)B062-20160331
000299783 980__ $$aI:(DE-He78)HD01-20160331
000299783 980__ $$aUNRESTRICTED